Shares of Genmab A/S (OTCMKTS:GNMSF – Get Free Report) gapped up before the market opened on Wednesday . The stock had previously closed at $329.25, but opened at $342.00. Genmab A/S shares last traded at $342.00, with a volume of 508 shares trading hands.
Genmab A/S Price Performance
The business’s 50 day moving average is $308.36 and its two-hundred day moving average is $281.58. The company has a debt-to-equity ratio of 0.81, a quick ratio of 2.44 and a current ratio of 2.46. The firm has a market capitalization of $21.06 billion, a PE ratio of 26.82 and a beta of 0.79.
Genmab A/S Company Profile
Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing antibody-based medicines for cancer and other serious diseases. Founded in 1999, the company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system and target disease-related cells.
Genmab’s products include Darzalex (daratumumab), developed with Janssen Biotech for certain blood cancers; Epkinly (epcoritamab), developed with AbbVie for certain types of B-cell lymphoma; and Tivdak (tisotumab vedotin), developed with Seagen, now part of Pfizer, for recurrent or metastatic cervical cancer.
Further Reading
- Five stocks we like better than Genmab A/S
- Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
- The Ultimate Cyber Shield: CrowdStrike Rises Past $235
- Palantir Just Told Wall Street Where AI Infrastructure Is Headed
- Homebuilders Are Down for the Year, Is Wall Street in Denial?
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
